In this ERDF project, a Brabants and Limburgs consortium will develop a fast, low-threshold and reliable measuring device with which the operation of Direct Oral Anti-Coagulants can be determined in an individual thrombosis patient, in a cheap and low-threshold way. There will be collaboration with Maastricht University, where clinical tests will be carried out and end users will be directly involved in this OPZuid project. The whole will be validated and demonstrated in practice (from TRL 5 to TRL 8). This project contributes to the health transition, as described in the regional policy of the South of the Netherlands. A specific contribution is made to the theme of ‘personalisation’ because this new measurement method allows for highly personalised treatment for a very large group of patients.